The primary goals of treatment of Sjögren’s syndrome (SS) are to relieve the hallmark sicca symptoms and minimize the impact and progression of systemic disease manifestations. Although an array of symptomatic therapies are available to help manage these symptoms, no medication is approved to treat the underlying autoimmune processes in SS. As such, clinicians rely on marketed therapies used to treat other autoimmune diseases, despite the limited availability of clinical data supporting their use. This content will quantitatively explore the current treatment of SS as marketed biologics and novel agents advance in the pipeline.
- Which systemic disease manifestations are most common among the patient populations of surveyed rheumatologists? Which are the most challenging manifestations to manage? Which diagnostic tests and severity scoring criteria do clinicians use in clinical practice?
- How do rheumatologists approach the management of sicca symptoms and systemic manifestations in primary and secondary SS patients?
- Which drugs are the patient-share leaders in SS? What clinical factors drive the selection of key queried agents (e.g., hydroxychloroquine, Roche/Genentech’s Rituxan)? What are the most common reasons for patients to discontinue key systemic or symptomatic agents?
- Which SS patients receive biologics (e.g., Roche/Genentech’s Rituxan, Bristol-Myers Squibb’s Orencia) and in which line(s) of therapy?
- What factors drive movement of SS patients through lines of therapy? With which of the queried medications for SS are patients most compliant?
- How has respondents’ prescribing for SS changed in the past year, and what changes do they expect in the year to come?
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
- Detailed, Expanded Analysis (US)
- Current Treatment Physician Insights Sjogren's Syndrome US October 2019
Author(s): John Crowley
John leads DRG’s Infectious, Niche, & Rare Diseases team and manages the market research portfolio across niche and rare diseases, anti-infectives, and vaccines. Prior to his current role, he was a Director on the team overseeing syndicated and custom work on niche and rare disease markets, as well as atopic dermatitis content in DRG’s Dermatology portfolio. He also served as a DRG analyst in the neurology space, focused mainly on the multiple sclerosis market. John holds a from the University of Massachusetts Medical School and a Bachelor’s degree from Worcester Polytechnic Institute.